Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Stem Cell Therapeutics

This page shows the latest Stem Cell Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Bayer helps bankroll new stem cell company BlueRock

Bayer helps bankroll new stem cell company BlueRock

Bayer helps bankroll new stem cell company BlueRock. Start-up receives $225m to develop cardiovascular and neurodegenerative disease therapies. ... There is a new player on the stem cell therapy stage, thanks to $225m in start-up funding from Bayer and

Latest news

  • Orphan status for Stem Cell's leukaemia drug Orphan status for Stem Cell's leukaemia drug

    US regulators have granted orphan drug status to tigecycline, a cancer drug in development by Stem Cell Therapeutics. ... Studies have demonstrated that the drug can target leukaemia cells by inhibiting certain proteins, however, influencing the Stem

  • ViaCyte appoints biotech veteran Paul Laikind as CEO

    ViaCyte appoints biotech veteran Paul Laikind as CEO. Will lead US firm's efforts to develop stem-cell therapy for people with diabetes. ... ViaCyte addresses one of the largest commercial and medical opportunities in stem-cell-derived therapeutics, and

  • The development of stem cell therapies The development of stem cell therapies

    In Europe, stem cell therapies are classified as 'advanced therapy medicinal products' (ATMPs). ... Other advances in the area of cardiovascular stem cell therapies include Cytori Therapeutics' adipose-derived stem and regenerative cells (ADRCs), which

  • UK regenerative medicine projects get £8.5m boost

    Novel stem cell manufacturing technologies. • Cell labelling and tracking technologies for quality control and monitoring in the body. • ... Regenerative medicine is an interdisciplinary approach that spans tissue engineering, developmental and stem

  • Survival strategy

    Licenser/Partner. Product/Technology. Development status. Headline ($m). Mesoblast/Cephalon. Stem cell therapeutics in CHF. ... Insulin producing beta cell regeneration. Preclinical. 349. Grunenthal/Gedeon Richter. Oral contraceptive range.

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    Commercialisation. Oralair, grass allergy sublingual tablet (pre-registration). 120. Osiris Therapeutics / Mesoblast . ... Asset acquisition. Mesenchymal stem cell business, including Prochymal (approved). 100. † Hutchison MediPharma / Eli Lilly.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Quick links

Infographics

Multimedia